EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data

Jiwon Kim iD, Chiwook Chung, Hyo Sin Cho, Ho Cheol Kim iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Jiwon Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Drug Tapering, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asan Institute for Life Sciences, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction.

Methods

This single-center retrospective cohort study included 156 consecutive patients with IPF who received pirfenidone. Demographic characteristics, pulmonary function, and pirfenidone-related adverse events were investigated. We compared patients who received standard and reduced doses of pirfenidone.

Results

The mean patient age was 69.7 years. The median follow-up duration was 243 days. The low-dose group (n = 73) included older patients (71.0 years vs. 67.4 years, p = 0.016), fewer smokers (80.8% vs. 96.4%, p = 0.008), and patients with a lower body mass index (BMI; 24.1 kg/m 2 vs. 25.7 kg/m 2 , p = 0.027) than the standard dose group (n = 57). Multivariate logistic regression analysis revealed that older age (odds ratio = 1.066, p = 0.016) was significantly associated with dose reduction of pirfenidone after adjusting for sex, smoking history, emphysema, and BMI. No significant difference was found in the rates of a reduced forced vital capacity and diffusing capacity for carbon monoxide between the two groups.

Conclusions

Although older patients are more likely to undergo dose reduction of pirfenidone, low-dose pirfenidone might be effective for treating patients with IPF. Low-dose pirfenidone could be considered an effective treatment option for older patients with IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug TaperingIdiopathic Pulmonary FibrosisHumansAgedRetrospective StudiesAnti-Inflammatory Agents, Non-SteroidalPyridonesTreatment OutcomeVital Capacity

Substanzen

pirfenidoneAnti-Inflammatory Agents, Non-SteroidalPyridones

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jiwon Kim, Ho Cheol Kim

Förderung

  • Asan Institute for Life Sciences
  • Ministry of Education

Zitieren

APA

Kim, J., Chung, C., Cho, H. S., & Kim, H. C. (2023). Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. PLOS ONE. https://doi.org/10.1371/journal.pone.0281295

Vancouver

Kim J, Chung C, Cho HS, Kim HC. Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. PLOS ONE. 2023. doi:10.1371/journal.pone.0281295

BibTeX
@article{Kim2023,
  author = {Kim, Jiwon and Chung, Chiwook and Cho, Hyo Sin and Kim, Ho Cheol},
  title = {Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281295}
}
Kostenlos starten →